Janssen
-
J&J Drug for Rare Infant Blood Disorder Achieves Main Goal of Phase 2 Test
A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.
-
J&J Stops Work on HIV Vaccine After Failure in Phase 3 Clinical Trial
Johnson & Johnson is stopping clinical development of an experimental HIV vaccine after the four-shot regimen did not beat a placebo in a late-stage study. The clinical trial failure comes follows the 2021 failure of the vaccine candidate in a different study population.
-
Streamline the Process for Consent Collection and Management
Join us on April 16th and hear executives from DocuSign and Velatura discuss how their partnership modernizes and facilitates the efficient and secure completion of the patient consent form.
-
Experts Unpack the True Meaning Behind 3 Healthcare Buzzwords
A panel of healthcare data experts recently broke down some of healthcare’s most common buzzwords at HLTH. While the experts agreed that many industry professionals still struggle to grasp the true denotations of words and phrases like “interoperability” and “reimagining healthcare,” the panelists said these terms can be quite meaningful once they’re unpacked.
-
Imagine a world without disease
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
-
BioPharma, Patient Engagement, Pharma, SYN
Verily joins with Janssen, adding Covid-19 to Project Baseline study
Verily and Janssen say studying Covid-19 immune responses could yield data that helps clinicians treat the disease. They add that the research could also apply to other illnesses caused by respiratory pathogens.
-
Verana strikes research collaboration with Janssen on ophthalmology and urology
Data analytics startup Verana Health struck a partnership with Janssen Research & Development. They’ll focus on exploring better treatments for diabetic retinopathy and macular edema.
-
Thermo Fisher, J&J partner on next-generation sequencing diagnostic for cancer clinical trials
The deal will focus in particular on developing an NGS-based companion diagnostic to aid enrollment in clinical trials, especially for non-small cell lung cancer. Thermo Fisher signed a similar deal with Eli Lilly in September.
-
FDA to rule on Sanofi’s myeloma drug by April of next year
The French drugmaker said the agency had accepted its application for isatuximab, a potential competitor to J&J’s Darzalex. Positive Phase III data for isatuximab were presented at the ASCO meeting last month.
-
Denmark’s Genmab files for $500M Nasdaq listing in US
The company, whose FDA-approved products include the myeloma drug Darzalex and the chronic leukemia drug Arzerra, hopes to launch its own proprietary product by 2025.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
FDA approves Janssen’s Balversa for urothelial carcinoma – with a personalized medicine approach
The drug was approved along with a companion diagnostic to detect alterations in FGFR2 and FGFR3. The drug is approved for patients with locally advanced or metastatic UC who carry those mutations.
-
FDA approves J&J’s Spravato as first novel antidepressant in decades
The drug, a reformulation of ketamine, was approved for patients who have failed on other antidepressants. The original form of ketamine, approved as an anesthetic, has long been explored as a treatment for depression.
-
Senate committee panel puts drug industry CEOs on defensive over pricing
The Senate Finance Committee grilled executives from seven of the biggest drugmakers about the dramatic rise in drug costs.
-
China’s BeiGene gets FDA breakthrough therapy designation for BTK inhibitor
While zanubrutinib showed a higher response rate in the same mantle cell lymphoma setting for which Imbruvica is approved, the Phase II study enrolled younger, less heavily pretreated patients than those in Imbruvica’s pivotal trial.
-
Aro Biotherapeutics draws $13M in startup investment to target centyrin proteins
The company currently has a product candidate in the late-discovery phase, an EGFR-targeting drug for lung cancer that would go after a resistance mechanism against existing kinase inhibitors.
-
2018 ASH meeting to feature new CAR-T therapies for myeloma
Bispecific antibodies like Amgen’s AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies – which target the same antigen – be possible?